Stop Retinal Ganglion Cell Dysfunction Study
Key facts
- Who runs it
- University of Miami
- Where
- Miami, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 28 people enrolled
- Started
- Sept 2015
- Ended
- 4 Oct 2024
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Latanoprost
- Bimatoprost
- Travoprost
- Timolol
- Dorzolamide
- Brinzolamide
- Acetazolamide
- Methazolamide
- Record updated
- 26 August 2025
- Why it stopped
- No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18 to 85 years, inclusive
- Refractive errors within -5 to +3 diopters
- Best corrected visual acuity (BCVA) better than or equal to 20/30 (Snellen)
- Normal standard automated perimetry (SAP) according to the Ocular Hypertension Treatment Study (OHTS) criteria15 (reliability < 15% on all indices, normality > 5% on all global indices in two consecutive sessions 6 months apart)
- Minimum untreated Intraocular pressure IOP of 15 mm Hg
- Glaucoma Suspect Status defined as one or more of the following:; Glaucomatous optic disc appearance (vertical cup-to-disc ratio [C/D] ≥0.5; Cup disc ratio asymmetry ≥0.2; Localized thinning of the disc; Presence or history of splinter disc hemorrhage; Moderately increased IOP (>21 to <28 mm Hg); Family history of vision loss for glaucoma
Who cannot take part
- Currently using prescribed pressure lowering medicines and unwilling to be withdrawn from them
- Diabetes
- Parkinson's disease
- Age-related macular degeneration
- Multiple sclerosis
- Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
- Pregnant or nursing women
- An OHTS risk score high enough in the judgment of the ophthalmologist or optometrist managing the patient to recommend pressure lowering medicine to the patient and not randomization
- An OCT abnormal enough in a pattern consistent with glaucoma
Where in United States
- Bascom Palmer Eye Institute - University of MiamiMiami, United States
About the trial
What the trial wants to find out
Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a population of glaucoma suspects (with positive factors for the disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests every 6 months over 4 years.
The 3 groups in the trial
- Abnormal PERG UntreatedNo study treatment, for comparison
Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
- Abnormal PERG TreatedTreatment being tested
Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%. Drugs could be: Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation. If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure.
Treatment: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, and Methazolamide
- NormalNo study treatment, for comparison
Patients with a normal PERG test that will go through the study under observation.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 August 2025